Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing.

Background: Activating mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) are predictive biomarkers for response to EGFR-tyrosine kinase inhibitor (TKI) therapy in lung adenocarcinoma (LUAD). Here, we characterized the clinicopathologic features associated with EGFR mutations via peptide nucleic acid clamping-assisted fluorescence melting curve analysis (PANAMutyper) and evaluated the feasibility of targeted deep sequencing for detecting the mutations.

Methods: We examined EGFR mutations in exons 18 through 21 for 2,088 LUADs from July 2017 to April 2020 using PANAMutyper.

Clinical evaluation of a droplet digital PCR assay for detecting mutations and molecular classification of endometrial cancer.

Objective: We evaluated droplet digital polymerase chain reaction (ddPCR) method for detecting mutations in endometrial cancer (EC) and guiding its molecular classification.

Methods: We reviewed 240 EC specimens from our hospital database. A ddPCR assay was used to identify mutations at 5 known hotspots (P286R, S297F, V411L, A456P, and S459F).